Shin-Etsu Chemical to further drive forward its QST® substrate business for implementation in GaN power devices
5.9.2023 06:00:00 EEST | Business Wire | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh) has determined that QST® (Qromis Substrate Technology) substrate*1 is an essential material for the social implementation of high-performance, energy-efficient GaN (gallium nitride) power devices, and the company will promote the development and launching on the market of these products.
Since QST® substrate is designed to have the same coefficient of thermal expansion (CTE) as GaN, it enables suppression of warpage and cracking of the GaN epitaxial layer and resultant large-diameter, high-quality thick GaN epitaxial growth. Taking advantage of these characteristics, it is expected to be applied to power devices and RF devices (5G and beyond 5G), which have been rapidly growing in recent years, as well as in such areas as MicroLED growth for MicroLED displays.
In addition to sales of QST® substrates, Shin-Etsu Chemical will also sell GaN grown QST® substrates upon customer request. We currently have a line-up of 6" and 8" diameter substrates, and we are working on 12" diameter substrates. Since 2021, for each respective application for power devices, RF devices and LEDs, sample evaluation and device development are continuing with numerous customers in Japan and globally. Especially for power devices, continuous evaluation is underway for devices in the wide range of 650V to 1800V.
So far, Shin-Etsu Chemical has repeatedly made many improvements with regard to its QST® substrates. One example is the significant improvement in lowering defects originating from the bonding process, which has enabled the supply of high-quality QST® substrates. In addition, for the thicker GaN films that many of our customers have requested, we have promoted the provision of template substrates with optimized buffer layers, which enables our customers to realize stable epitaxial growth of more than 10 μm thickness. Furthermore, various successful results have been produced and reported on, including the achievement of thick-film GaN growth exceeding 20 μm using QST® substrates and the achievement of 1800V breakdown voltage*2 in power devices.
Moreover, Shin-Etsu Chemical and Oki Electric Industry Co., Ltd. have jointly succeeded in developing a technology to exfoliate GaN from QST® substrates and bond it to substrates made of different materials using Crystal Film Bonding (CFB)*3 technology. Until now, most GaN power devices have been lateral devices, but CFB technology takes advantage of the characteristics of QST® substrates to realize vertical power devices that can control large currents by exfoliating a thick layer of high-quality GaN from an insulating QST® substrate. To customers who manufacture GaN devices, Shin-Etsu Chemical will provide QST® substrates or GaN grown QST® substrates and Oki Electric Industry will provide its CFB technology through partnering or licensing. In this way, the two companies hope to contribute to the advancement of vertical power devices.
Based on these development results and also based on business situation inquiries from customers, Shin-Etsu Chemical will continue to increase production to meet customer demand.
Shin-Etsu Chemical will contribute to the realization of a sustainable society that can use energy efficiently by further promoting the social implementation of GaN devices that have characteristics that are absolutely essential for the future society.
Shin-Etsu Chemical will make a presentation on the progress in the development of this product at SEMICON Taiwan, which will be held in Taiwan from September 6 to 8, 2023.
*1: A QST® substrate is a composite material substrate developed by Qromis, Inc. (Head Office: Santa Clara, California; CEO Cem Basceri) exclusively for GaN growth and was licensed to Shin-Etsu Chemical in 2019. QST® is a registered trademark held by Qromis, Inc. in the United States (registration number 5277631).
*2: Please refer to the following imec release (April 2021).
https://www.imec-int.com/en/press/imec-and-aixtron-demonstrate-200-mm-gan-epitaxy-aix-g5-c-1200v-applications-breakdown-excess
*3: CFB technology is a technology to exfoliate GaN epitaxial layers from substrates and is a registered trademark of Oki Electric Industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904363382/en/
Contact information
For inquiries about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-6812-2340, or from outside Japan: 81-3-6812-2340
Fax: 03-6812-2341, or from outside Japan: 81-3-6812-2341
E-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network capability, the only such offering among pure-play event technology providers in Europe, en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
